HMG 75iu

• Active ingredient: Human menopausal gonadotropin (hMG). Each vial contains highly-purified human menopausal gonadotropin (HMG) corresponding to 75 IU of follicle-stimulating hormone (FSH) and 75 IU of luteinizing hormone (LH).
• Type: Peptide hormone
• Form: Injections

Description

Human menopausal gonadotropin (hMG) is a medication used to treat fertility disturbances in both men and women. It is a mixture of two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

Mechanism of action

When injected, hMG is absorbed into the body through the muscle tissue. It stimulates testosterone production and has gained popularity in anti-aging clinics and biotechnology companies.

HMG differs from HCG in its binding properties. While HCG primarily binds to LH receptors, HMG naturally binds to both LH and FSH receptors. HMG promotes sperm maturation and differentiation, in addition to increasing testicular size, libido, and mood. It is important for maintaining testicular activity and preventing atrophy.

HMG is primarily excreted via the kidneys, and its pharmacokinetics in patients with renal or hepatic impairment have not been extensively studied.

Purpose of use

HMG was initially developed to treat female infertility but is also used in hormone replacement therapy for men. In bodybuilding, HMG is commonly used in post-cycle therapy (PCT) to support testicular activity and fertility. Combining HCG and HMG has shown superior recovery after steroid cycles.

How to use

Treatment with HMG should be initiated under the supervision of a physician experienced in fertility treatments. Dosage and duration of treatment will vary depending on individual response. HMG can be used alone or in combination with a GnRH agonist or antagonist, depending on the treatment protocol.

For preserving testicular activity during steroid cycles longer than 10 weeks, it is recommended to start using HMG from the first week to prevent atrophy. The typical protocol involves HMG injections at a dose of 75-150 IU 2-3 times per week, along with HCG injections at a dose of 250-500 IU 2-3 times per week. Hypogonadotropic hypogonadism may require a dosage of 5-10 IU per day for several months.

Athletes seeking performance enhancement may take up to 10 IU per day, with an additional 5 IU dose 30 minutes before workouts on training days.

In cases of severe anabolic steroid-induced azoospermia, a protocol of twice-weekly injections of 10,000 IU of HCG and daily injections of 75 IU of HMG for 3 months has been used. Care should be taken to avoid overstimulation of Leydig cells.

How to prepare a solution

To prepare the injection solution, draw a diluent into a syringe and inject it into the vial containing the lyophilized powder. Tilt the vial so that the needle touches the vial wall, allowing the diluent to flow down gradually. Gently mix the solution without agitating or shaking the vial until the ly ophilized powder is completely dissolved, resulting in a clear liquid. Avoid mixing different peptides in the same syringe.

Administration

• The injection can be administered subcutaneously or intramuscularly, based on personal preference.

Effects

• Increased endogenous testosterone levels
• Increased production of spermatozoa
• Improved libido and mood
• Restoration of fertility
• Preservation of testicular activity during steroid cycles
• Possibility of restoring natural testosterone production and fertility after steroid abuse

Side effects

• Abdominal pain
• Shortness of breath
• Breast swelling
• Tender breasts
• Nausea
• Weight gain
• Swelling of the hands and feet
• Mild skin rash
• Testicular pain

Drug profile

• Half-life: LH (13.8-1020 minutes) and FSH (21.3-1090 minutes)
• Frequency of intake: Once every 3 days

Contraindications

• Hypersensitivity to menotropin or any of the excipients in the medication
• Women with tumors of the pituitary gland or hypothalamus, ovarian, uterine, or mammary carcinoma, gynecological hemorrhage of unknown cause, or ovarian cysts or enlarged ovaries not due to polycystic ovarian disease
• Treatment outcome is unlikely to be favorable in primary ovarian failure, malformation of sexual organs incompatible with pregnancy, or fibroid tumors of the uterus incompatible with pregnancy
• Use during pregnancy or lactation is contraindicated

Injections

1. Use an insulin syringe for subcutaneous or intramuscular injections.
2. Disinfect the rubber cap of the vial and the injection site with alcohol.
3. Draw the medication into the syringe and inject it slowly.

Storage

• Store the medication protected from light.
• Keep it in a refrigerator at a temperature of 2-8°C.
• Do not freeze.
• After reconstitution, the solution may be stored for a maximum of 28 days at a temperature not exceeding 25°C.
• After dissolution in the included solvent, the solution should be administered immediately.
• Keep it away from children and do not use it after the expiry date.